Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.33 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.33 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.33 |
| ▸ | IDO1 | P14902 | 1/20 | 0.32 |
| ▸ | FASN | P49327 | 1/20 | 0.31 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | BLM | P54132 | 1/20 | 0.31 |
| ▸ | GRM7 | Q14831 | 3/20 | 0.30 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.30 |
| ▸ | KDM5A | P29375 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19198696 | 0.88 | IDO1 (0.38) | POLBTSHRKMT2AMTNR1AMTNR1B | |
| SCHEMBL25854711 | 0.81 | TSHR (0.33) | POLBTSHRKMT2AMTNR1AMTNR1B | |
| SCHEMBL25697715 | 0.80 | TSHR (0.41) | POLBTSHRKMT2AMTNR1AMTNR1B | |
| SCHEMBL23570683 | 0.78 | MTNR1A (0.33) | POLBTSHRKMT2AMTNR1AMTNR1B | |
| SCHEMBL16144280 | 0.78 | MTNR1A (0.31) | MTNR1AMTNR1BEPHX2 | |
| SCHEMBL12786289 | 0.77 | GAA (0.48) | POLBTSHRKMT2AMTNR1AMTNR1B | |
| SCHEMBL2595410 | 0.77 | MAOB (0.40) | POLBTSHRKMT2AKDM5A | |
| SCHEMBL16538343 | 0.76 | EPHX2 (0.56) | MTNR1AMTNR1BEPHX2IDO1HSD11B1 | |
| SCHEMBL24334237 | 0.76 | GAA (0.32) | POLBTSHRKMT2AMTNR1AMTNR1B | |
| SCHEMBL16144313 | 0.75 | TBK1 (0.32) | EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9018200-B2 | Substituted piperidinyl compounds useful as GPR119 agonists | MERCK SHARP & DOHME CORP. (US) | 2015-04-28 | — | — | US | disclosed |
| US-20140296202-A1 | SUBSTITUTED PIPERIDINYL COMPOUNDS USEFUL AS GPR119 AGONISTS | MERCK SHARP & DOHME CORP. (US) | 2014-10-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140296202-A1 | SUBSTITUTED PIPERIDINYL COMPOUNDS USEFUL AS GPR119 AGONISTS | GPR119, GPR27, GPR139 | POLB 3994/4885TSHR 569/4885KMT2A 3752/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.